• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

垂体腺瘤中的端粒长度和端粒酶逆转录酶异常

Telomere length and TERT abnormalities in pituitary adenomas.

作者信息

Boresowicz Joanna, Kober Paulina, Rusetska Nataliia, Maksymowicz Maria, Goryca Krzysztof, Kunicki Jacek, Bonicki Wiesław, Bujko Mateusz

机构信息

Department of Molecular and Translational Oncology, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland.

Department of Pathology and Laboratory Diagnostics, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Poland.

出版信息

Neuro Endocrinol Lett. 2018 Mar;39(1):49-55.

PMID:29803207
Abstract

OBJECTIVES

Pituitary adenomas (PAs) are among the most frequent intracranial tumors in humans. Abnormal telomerase activity and telomere lengthening are features of tumor cells. They may result from mutations in TERT promoter region, gene amplification or aberrant DNA methylation pattern. Such changes were found in variety of tumors including those of brain. Aim of the study was to evaluate the incidence of TERT abnormalities and to assess their role in telomere lengthening in PAs.

METHODS

Study involved 101 patients with PA including both nonfunctioning and functioning subtypes. Telomerase length as well as TERT mRNA level and gene amplification were estimated using quantitative PCR (qPCR). Promoter mutations were assessed using Sanger sequencing. The results from genome-wide DNA methylation profiling with HumanMethylation 450K (Illumina) were used for the analysis of TERT locus.

RESULTS

Variable telomere length was observed in patients, however no relationship with clinicopathological features was found. We observed a missense variant in TERT promoter in one patient only whereas increased TERT copy number were identified in 6 patients (5.6%). However no relationship between these results and telomere length or TERT expression was found. DNA methylation at TERT locus was not found to be changed when adenoma samples and normal tissue sections were compared.

CONCLUSION

The results indicate that telomerase abnormalities do not play a role in pathogenesis of pituitary tumors.

摘要

目的

垂体腺瘤(PAs)是人类最常见的颅内肿瘤之一。端粒酶活性异常和端粒延长是肿瘤细胞的特征。它们可能源于TERT启动子区域的突变、基因扩增或异常的DNA甲基化模式。在包括脑肿瘤在内的多种肿瘤中都发现了此类变化。本研究的目的是评估TERT异常的发生率,并评估它们在垂体腺瘤端粒延长中的作用。

方法

研究纳入了101例垂体腺瘤患者,包括无功能型和有功能型亚型。使用定量PCR(qPCR)估计端粒酶长度以及TERT mRNA水平和基因扩增情况。使用桑格测序法评估启动子突变。来自HumanMethylation 450K(Illumina)全基因组DNA甲基化谱分析的结果用于TERT基因座的分析。

结果

在患者中观察到端粒长度存在差异,但未发现与临床病理特征有相关性。仅在1例患者中观察到TERT启动子的错义变异,而在6例患者(5.6%)中鉴定出TERT拷贝数增加。然而,未发现这些结果与端粒长度或TERT表达之间存在相关性。比较腺瘤样本和正常组织切片时,未发现TERT基因座的DNA甲基化发生变化。

结论

结果表明端粒酶异常在垂体肿瘤发病机制中不起作用。

相似文献

1
Telomere length and TERT abnormalities in pituitary adenomas.垂体腺瘤中的端粒长度和端粒酶逆转录酶异常
Neuro Endocrinol Lett. 2018 Mar;39(1):49-55.
2
TERT promoter methylation is significantly associated with TERT upregulation and disease progression in pituitary adenomas.TERT 启动子甲基化与垂体腺瘤中 TERT 的上调和疾病进展显著相关。
J Neurooncol. 2019 Jan;141(1):131-138. doi: 10.1007/s11060-018-03016-8. Epub 2018 Nov 3.
3
TERT promoter hypermethylation is associated with poor prognosis in adrenocortical carcinoma.TERT 启动子甲基化与肾上腺皮质癌的预后不良相关。
Int J Mol Med. 2018 Sep;42(3):1675-1683. doi: 10.3892/ijmm.2018.3735. Epub 2018 Jun 20.
4
N-myc downstream-regulated gene 2 (NDRG2) promoter methylation and expression in pituitary adenoma.垂体腺瘤中N-myc下游调控基因2(NDRG2)的启动子甲基化与表达
Diagn Pathol. 2017 Apr 8;12(1):33. doi: 10.1186/s13000-017-0622-7.
5
TERT promoter mutation as an early genetic event activating telomerase in follicular thyroid adenoma (FTA) and atypical FTA.TERT 启动子突变作为早期遗传事件,激活滤泡状甲状腺腺瘤(FTA)和非典型 FTA 中的端粒酶。
Cancer. 2014 Oct 1;120(19):2965-79. doi: 10.1002/cncr.28800. Epub 2014 Jun 4.
6
DNA methylation profiling in nonfunctioning pituitary adenomas.非功能性垂体腺瘤中的 DNA 甲基化分析。
Mol Cell Endocrinol. 2018 Sep 15;473:194-204. doi: 10.1016/j.mce.2018.01.020. Epub 2018 Feb 1.
7
Telomerase activation in small intestinal neuroendocrine tumours is associated with aberrant promoter methylation, but not hot-spot mutations.小肠神经内分泌肿瘤中端粒酶的激活与启动子异常甲基化有关,但与热点突变无关。
Epigenetics. 2019 Dec;14(12):1224-1233. doi: 10.1080/15592294.2019.1634987. Epub 2019 Jul 19.
8
TERT promoter hotspot mutations and their relationship with TERT levels and telomere erosion in patients with head and neck squamous cell carcinoma.TERT 启动子热点突变及其与头颈鳞癌患者 TERT 水平和端粒侵蚀的关系。
J Cancer Res Clin Oncol. 2020 Feb;146(2):381-389. doi: 10.1007/s00432-020-03130-z. Epub 2020 Jan 20.
9
hTERT promoter methylation in pituitary adenomas.垂体腺瘤中的人端粒酶逆转录酶启动子甲基化
Brain Tumor Pathol. 2016 Jan;33(1):27-34. doi: 10.1007/s10014-015-0230-8. Epub 2015 Sep 21.
10
Telomere length and telomerase expression in pituitary tumors.垂体肿瘤中的端粒长度与端粒酶表达
J Endocrinol Invest. 2015 Nov;38(11):1243-6. doi: 10.1007/s40618-015-0298-3. Epub 2015 May 8.

引用本文的文献

1
DNA Methylation in Pituitary Adenomas: A Scoping Review.垂体腺瘤中的DNA甲基化:一项范围综述
Int J Mol Sci. 2025 Jan 10;26(2):531. doi: 10.3390/ijms26020531.
2
Molecular Markers of Telomerase Complex for Patients with Pituitary Adenoma.垂体腺瘤患者端粒酶复合物的分子标志物
Brain Sci. 2022 Jul 25;12(8):980. doi: 10.3390/brainsci12080980.
3
Telomerase expression in clinically non-functioning pituitary adenomas.临床上无功能垂体腺瘤中的端粒酶表达。
Endocrine. 2021 Apr;72(1):208-215. doi: 10.1007/s12020-020-02524-w. Epub 2020 Oct 22.
4
The Epigenomics of Pituitary Adenoma.垂体腺瘤的表观基因组学
Front Endocrinol (Lausanne). 2019 May 14;10:290. doi: 10.3389/fendo.2019.00290. eCollection 2019.